Glucagon-like peptide-1 increases heart rate by a direct action on the sinus node, Cardiovascular Research (2024) Semaglutide and cardiovascular outcomes in obesity without diabetes, The New England Journal of Medicine (2023) Real-world safety profile of once-weekly semaglutide in people with type 2 diabetes: Analysis of pooled data from the SemaglUtide Real-world Evidence (SURE) programme, Diabetes, Obesity and Metabolism (2024) Ozempic (semaglutide injection) product monograph (2018) Tachycardia, Mayo Clinic (2023) How to check your heart rate (manually and using a device), Mass General Brigham (2025) Target Heart Rates Chart, American Heart Association (2025) Craig D
Clinical response: Review dosage and consider slowing titration
p=3.110 -12 ) and disease activity (NAS=2
J Am Pharmacists Assoc 2023;63:1643-1645
Treatment benefits to patients can be achieved by enhancing the therapeutic efficiency, with a less toxic profile and number of doses required as compared to the comparator product
Safety varies by peptide type, source, dosage, and medical supervision